3P R O D U C T L I S T
2P R O D U C T L I S T
History
Activities of Samyang
R&D
Products
3
5
6
7
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Relocation of Daejeon R&D Center and Seoul HQ to Samyang Discovery Center in Pangyo
Launched the Oxidized Regenerated Cellulose Adhesion Barrier InterGuard®Launched the Oxidized Regenerated Cellulose hemostat SurgiGuard®
EU GMP for API(extention) German AuthoritiesLaunched Endoscopic Sugical Loop, Neosorb® Loop & Monosorb® Loop
Samyang Biopharm and Samyang Genex Bio merged into one companyDrug-contained suture (Neosorb® Plus) was approvedLaunched the painkiller Fentaderm® patchLaunched the oral-disintegrating drug antinauseant Imestop®Launched the anticancer drug Nanoxel® M Injection
2012 12 Hit 100,000 km annual surgical suture sales (in terms of bulk volume)Launched the anticancer adjuvant Zolenic® InjectionThe anticancer drug Nanoxel®M Injection was approvedLaunched the surgical sutures Monosorb® Plus and Monofast® PlusThe antinauseant Emestop® Injection was approvedDesignated as an innovative pharmaceutical company by the Ministry of Health and WelfareSamyang Genex spun off Samyang Genex Bio (physical division)
Samyang Group transformed into a holding company structure Samyang Biopharmaceuticals Corporation established“Research Collaboration Agreement” reached with Takeda Pharmaceutical co., Ltd. for discovering a novel DDS platform technology for RNAi therapeutics
Australian TGA GMP certification for patch products received
Launched Antibacterial absorbable braided suture material, Neosorb PlusIran GMP certification for pharmaceuticals received
Docetaxel-PNP receives IND approvalNanoxel injection(docetaxel) approvedNicostop Gum approvedGenexol-PM approved in IndiaGenexol-PM receives IND approval (phase II on ovarian cancer)Genexol-PM approved in VietnamGenexol-PM approved in PhilippineAnti-adhesion Barrier Poligogel receives IND approvalGenexol approved in SerbiaGenexol-PM receives IND approval (phase I on ovarian cancer)
Docetaxel-PM receives IND approvalCapsaicin plaster IND approval Loratadine FDT approvedSuture Neosorb approved
Partially Absorbable Surgical mesh Proflex approvedGenexol-PM wins Korea New Drug Award GENEXOL-PM™ (next generation anti-cancer agent using Paclitaxel, injection) marketed in Korea
Daedeok pharmaceutical plant extended Genexol-PM wins Health industry & technology awardLaunched Absorbable braided suture material, NeosorbMedical management information system built
Nicostop troche approvedNexatin injection(oxaliplatin) approvedLaunched Absorbable monofilament suture material, Monofast“Business Agreement” reached with Akina, Inc. of the U.S. on Cetirizine FDT
S E P.
OCT.
OCT.
NOV.
J U L .
J U L .
JUN.
MAY.
APR.
MAR.
DEC.
DEC.
DEC.
AUG.
AUG.
JUN.
APR.
NOV.
MAR.
MAR.
JUN.
JAN.
OCT.
AUG.
J U L .
J U L .
J U L .
JUN.
MAY.
APR.
JAN.
JAN.
NOV.
J U L .
JUN.
F E B .
J U L .
F E B .
F E B .
DEC.
DEC.
S E P.
JAN.
NOV.
NOV.
JUN.
MAR.
2016 2005
HistoryContents
5P R O D U C T L I S T
4P R O D U C T L I S T
Related businesses
Samyang Corporation
Mixed feeds Trading
Samyang Data Systems
Information technology
Samyang Entech Machinery Environment
Pharmaceutical
SamyangBiopharm
Patches Medical devices
Anti-cancers drugs
Chemicals
SamyangCorporation
Engineering plastics
Industrial fiber PET bottles PET bottle
recyclingIon exchange
resins
Samnam Petrochemical
TPA
SamyangKasei
Poly-carbonate
SamyangEngineering
Plastics (Shanghai)
Engineering Plastics
Samyang EMS Photoresist
Foodstuffs
SamyangCorporation
Sugar Flour Vegetable oils Baking & Batter mixes
Margarine & Shortening Olive oil Bakery
ingredientsHigh intensity
sweetener
SamyangGenex
Starch Corn sweeteners Polyols
Functional food
ingredients
SamyangMilmax
Flour Naaking & Batter mixes
SamyangWelfood
Margarine & shortening Vegetable oils
SevenSprings
Family restaurant
SamyangF&D
Bakery Cafe
SamyangGenex food
(Qinhuangdao)
Corn sweeteners
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
“R&D Agreement” reached with Hyundai Pharmaceutical of Korea on Cetirizine Hydrochloride FDT
Phase II clinical trials of Genexol PM on breast cancer II initiated at Asan Medical Center, etc.
Suture Monosorb-Pro approved
Genexol Injection certified as effective in gastric cancer treatment
“R&D Agreement” reached with Akina, Inc. of the U.S.
Phase II clinical trials of Genexol PM on non-small cell lung cancer initiated at Seoul National University Hospital, etc.
Phase II clinical trials of Genexol PM on breast cancer I initiated at Seoul National University Hospital, etc.
Genexol Injection certified as effective in ovarian cancer treatment
“R&D Agreement” reached with Lavipharm of Greece and technical Transfer of Nicostop completed
Genexol Injection certified as effective in lung cancer treatment
Pharmaceutical research corporation established in Utah Samyang Research Corporation(SRC)
Genexol-PM receives U.S. IND approval
100 mg Genexol-PM Injection approved
“Business Agreement” reached with Akina, Inc. of the U.S.
Genexol-PM Injection approved
Genexol Injection certified as effective in breast cancer treatment
“R&D Agreement” reached with Transform Pharmaceuticals, Inc. of the U.S.
“Business Agreement” reached with Transform Pharmaceuticals, Inc. of the U.S.
Surgisorb and BioMesh acquire CE mark
Three R&D Agreements reached with MacroMed, Inc. of the U.S. on hGH, pGH, Tramadol, and G-CSF
Medical devices acquire ISO 9001 & EN 46001 certification
BioMesh approved
KGMP certification for medical device received
Launched Absorbable monofilament suture material, Monosorb
Genexol Injection approved and released (Jun 1, 2001)
Reumastop Plaster approved
Surgisorb, an absorbable suture product, approved and released (Dec 1, 1998)
Nicostop patches approved
Trisorb wins Jang Young Shil Award
Launched 1st Absorbable braided suture material, Trisorb
KGMP certification for pharmaceuticals received
“Business Agreement” reached with AmCyte, Inc. of the U.S.
“Business Agreement” reached with VivoRx Pharmaceutical, Inc. of the U.S.
“R&D Agreement” reached with MacroMed, Inc. of the U.S. and Gene Delivery System developed
“R&D Agreement” reached with TheraTech, Inc. of the U.S. on Combitran-MTX
“R&D Agreement” reached with TheraTech, Inc. of the U.S. on Estran-MTX
Medical suture products win patented technology award
“R&D Agreement” reached with TheraTech, Inc. of the U.S. on Androderm-LRS and Angiderm-MTX patches
“Business Agreement” reached with MacroMed, Inc. of the U.S.
Medical suture products granted the Korea Good Technology mark
Pharmaceutical Research Center established
AUG.
JUN.
MAR.
F E B .
DEC.
AUG.
F E B .
F E B .
DEC.
JUN.
MAY.
F E B .
OCT.
JUN.
MAR.
MAR.
AUG.
AUG.
AUG.
MAR.
DEC.
S E P.
AUG.
J U L .
DEC.
DEC.
DEC.
JUN.
MAY.
NOV.
NOV.
AUG.
AUG.
AUG.
MAR.
DEC.
OCT.
JUN.
JAN.
OCT.
S E P.
2004 1992
Activities of SamyangHistory
6P R O D U C T L I S T
Samyang first established R&D center in 1979 and moved to its ultra-modern central R&D center in Daedeok science town in 1993. As part of effort to become a truly world class research center, academicians and scientists recognized in their fields from Korea and abroad were invited for Scientific Advisory Board(SAB).
Samyang decided to put its R&D resource to conduct research in the field of drug delivery system and biotechnology.
Samyang’s involvement in the research to develop novel drug delivery system began when it decided to make equity participation in Thera Tech U.S.A ; a company dedicated to the development of transdermal drug delivery systems. Since then Samyang has been nurturing its own in-house research to become a world class center for drug delivery system research.
Samyang’s expertise in polymer chemistry and its dedication to use proprietary biopolymer technologies to develop novel drug delivery systems has resulted in development of technology platforms with applications in cancer therapy, acute/chronic pain management, smoking cessation, hormone therapy, surgical wound management and more. The formulations developed cover various type of parenterals (enhanced bioavailabilty, sustained release and long articulating particles injections), transdermal patches, rapid dissolution tablets, colon targeting oral formulations, various types of suture materials and needles.
While focusing efforts on the in-house development of novel drug delivery system, we have continued to expand our technology portfolio. Samyang has invested in several new development stage companies that have proprietary technologies for future development of drug delivery systems. In line with its commitment to become a world class drug delivery system developing company, Samyang is prudently pursuing rigorous in-house R&D programs, internal collaboration and strategic alliances.
Samyang’s biotechnology related research activities are conducted at the Samyang Genex Research Institute located within its R&D center. The institute is engaged in plant-biology, therapeutic protein, gene-therapy research projects.
Plant biology research includes development plant cell culture technology to produce useful secondary metabolites from plants. The institute successfully produced paclitaxel, an important anti-cancer drug, by plant cell culture technology. The technology has been successfully scaled up to commercial scale and a dedicated plant is producing high quality paclitaxel bulk under cGMP and US FDA guidelines.
Samyang’s biotechnology-related research activities are conducted at Samyang Genex Biotechnology Research Center located within Samyang Group R&D Complex. Biotechnology Research Center is engaged in the plant biotechnology, microbial fermentation, and organic synthesis research. Researches on Plant Biotechnology involves development of plant cell culture technology for producing useful secondary metabolites from plant cells. Paclitaxel, an important anti-cancer drug, was the first commercial product of plant cell culture technology.
Samyang Genex is now producing the best quality paclitaxel at its Daejeon plant, which is compliant to cGMP (cGMP: current good manufacturing practice, US compliance) and has been certified by EU Authority (Germany). Samyang Genex’s paclitaxel has recently been approved for CEP from European Medicinal Agency. Microbial fermentation research focuses on the strain and process development of useful therapeutic intermediates and APIs (Active Pharmaceutical Ingredients). Recently, the Center has expanded its research scope to organic synthesis. The Center plans to expand the portfolio of anticancer therapeutics by combining intermediate production and semi-synthesis to produce a lot of interesting APIs.
P R O D U C T s
R&D
Trisorb®
Trisorb® II
Trisorb® Rapid
Trisorb® Plus
Neosorb®
Neosorb® Rapid
Neosorb® Plus
Monosorb®
Monosorb® Plus
Monofast®
Monofast® Plus
Monolene®
Surgisorb®
Proflex® Mesh
SurgiGuard® M
SurgiGuard®
InterGuard®
Biomesh®
8 9P R O D U C T L I S T P R O D U C T L I S T
Description Coated Synthetic Absorbable Braided PGA Suture material
Non-sterile bulk strand
IndicationStrand for further processing to finished sterilized sutures for human and veterinary use
Characteristics· Compliance with the requirements of USP and EP
· High tensile strength
· Excellent handling and knotting characteristics
- Smooth tissue passage
- Easy knotting and tie down
- Excellent knot security
· Reliable absorbability
specifications & Package
S y n t h e t i c A b s o r b a b l e B r a i d e d S u t u r e M a t e r i a l
IsO 13485Certified Quality System
S y n t h e t i c A b s o r b a b l e B r a i d e d S u t u r e M a t e r i a l
Description Coated Synthetic Absorbable Braided PGA Suture material
Non-sterile bulk strand
IndicationStrand for further processing to finished sterilized sutures for human and veterinary use
Characteristics· Higher tensile strength and better handling than Trisorb
· Compliance with the requirements of USP and EP
· High tensile strength
· Excellent handling and knotting characteristics
- Smooth tissue passage
- Easy knotting and tie down
- Excellent knot security
· Reliable absorbability
specifications & Package
IsO 13485Certified Quality System
Trisorb® IITrisorb®
Size Color & Packaging LengthCoating Materials
USP Metric 500m 1,000m
3,4 7,8
Ca-Stearate&
PCL
2 6
1 5
1-0 4
2-0 3.5
3-0 3
4-0 2
5-0 1.5
6-0 1
7-0 0.7
8-0 0.5
Size Color & Packaging LengthCoating Materials
USP Metric 500m 1,000m
2 6
Ca-Stearate&
PGA-PLA
1 5
1-0 4
2-0 3.5
3-0 3
4-0 2
5-0 1.5
6-0 1
7-0 0.7
8-0 0.5
10 11P R O D U C T L I S T P R O D U C T L I S T
F a s t A b s o r b a b l e B r a i d e d S u t u r e M a t e r i a l
Description Coated Synthetic Fast Absorbable Braided PGA Suture
IndicationSuperficial skin closure, scalp plastic surgery, episiotomy wound healing or oral mucosa.
Characteristics· Compliance with the requirements of USP and EP
· Reliable absorbability. (lose its breaking strength 9~11days after application)
· Available in the undyed form
specifications & Package
Antibacterial Synthetic Absorbable Braided Suture Material
DescriptionCoated Synthetic Absorbable Braided PGA Suture material
Antibacterial agent contained suture
Non-sterile bulk strand
IndicationStrand for further processing to finished sterilized sutures for human and veterinary use
Characteristics· Compliance with the requirements of USP and EP
· High tensile strength
· Excellent handling and knotting characteristics
- Smooth tissue passage
- Easy knotting and tie down
- Excellent knot security
· Reliable absorbability
specifications & Package
Trisorb® PlusTrisorb® Rapid
IsO 13485Certified Quality System
IsO 13485Certified Quality System
Size Color & Packaging LengthCoating Materials
USP Metric 500m 1,000m
1 5
Ca-Stearate&
PCL
1-0 4
2-0 3.5
3-0 3
4-0 2
5-0 1.5
6-0 1
Size Color & Packaging LengthCoating Materials
USP Metric 500m 1,000m
2 6
Ca-Stearate&
PGA-PLA&
CHA
1 5
1-0 4
2-0 3.5
3-0 3
4-0 2
5-0 1.5
12 13P R O D U C T L I S T P R O D U C T L I S T
S y n t h e t i c A b s o r b a b l e B r a i d e d S u t u r e M a t e r i a l
Description Coated Synthetic Absorbable Braided PGA-PLA(90:10) Suture material
Non-sterile bulk strand
IndicationStrand for further processing to finished sterilized sutures for human and veterinary use
Characteristics· Compliance with the requirements of USP and EP
· High tensile strength
· Excellent handling and knotting characteristics
- Smooth tissue passage
- Easy knotting and tie down
- Excellent knot security
· Reliable absorbability
specifications & Package
F a s t A b s o r b a b l e B r a i d e d S u t u r e M a t e r i a l
DescriptionCoated Synthetic Fast Absorbable Braided PGA-PLA(90:10) Suture material
IndicationSuperficial skin closure, scalp plastic surgery, episiotomy wound healing or oral mucosa.
Characteristics· Compliance with the requirements of USP and EP
· Reliable absorbability. (lose its breaking strength 5~8days after application)
· Available in the undyed form
specifications & Package
Neosorb® RapidNeosorb®
IsO 13485Certified Quality System
IsO 13485Certified Quality System
Size Color & Packaging LengthCoating Materials
USP Metric 500m 1,000m
2 6
Ca-Stearate&
PGA-PLA
1 5
1-0 4
2-0 3.5
3-0 3
4-0 2
5-0 1.5
6-0 1
7-0 0.7
8-0 0.5
Size Color & Packaging LengthCoating Materials
USP Metric 500m 1,000m
2 6
Ca-Stearate&
PGA-PLA
1 5
1-0 4
2-0 3.5
3-0 3
4-0 2
5-0 1.5
6-0 1
14 15P R O D U C T L I S T P R O D U C T L I S T
Antibacterial Synthetic Absorbable Braided Suture Material
Description Coated Synthetic Absorbable Braided PGA-PLA(90:10) Suture material
Antibacterial agent contained suture
Non-sterile bulk strand
IndicationStrand for further processing to finished sterilized sutures for human and veterinary use
Characteristics· Compliance with the requirements of USP and EP
· High tensile strength
· Excellent handling and knotting characteristics
- Smooth tissue passage
- Easy knotting and tie down
- Excellent knot security
· Reliable absorbability
specifications & Package
Description Synthetic Absorbable PDO Monofilament Suture material
Non-sterile bulk strand
IndicationStrand for further processing to finished sterilized sutures for human and veterinary use
Characteristics· Compliance with the requirements of EP
· Lower Incidence of Infection and Trauma due to Smooth Surface
· Smooth tissue passage
· Predictable loss and Higher strength compared to Catgut
specifications & Package
S y n t h e t i c A b s o r b a b l e M o n o f i l a m e n t S u t u r e M a t e r i a l
Monosorb®Neosorb® Plus
IsO 13485Certified Quality System
IsO 13485Certified Quality System
Size Color & Packaging LengthCoating Materials
USP Metric 500m 1,000m
2 6
Ca-Stearate&
PGA-PLA&
CHA
1 5
1-0 4
2-0 3.5
3-0 3
4-0 2
5-0 1.5
Size Color & Packaging LengthCoating Materials
USP Metric 500m 1,000m
2 6
N/A
1 5
1-0 4
2-0 3.5
3-0 3
4-0 2
5-0 1.5
6-0 1
7-0 0.7
16 17P R O D U C T L I S T P R O D U C T L I S T
Antibacterial Synthetic Absorbable Monofilament Suture Material
DescriptionSynthetic Absorbable PDO Monofilament Suture material
Antibacterial agent contained suture
Non-sterile bulk strand
IndicationStrand for further processing to finished sterilized sutures for human and
veterinary use
Characteristics· Compliance with the requirements of EP
· Lower Incidence of Infection and Trauma due to Smooth Surface
· Smooth tissue passage
· Predictable loss and Higher strength compared to Catgut
specifications & Package
Description Synthetic Fast Absorbable PGA-PCL(75/25) Monofilament Suture material
Non-sterile bulk strand
IndicationStrand for further processing to finished sterilized sutures for human and veterinary use
Characteristics· Compliance with the requirements of EP
· Excellent handling properties : Flexible, easy to tie
· Lower Incidence of Infection and Trauma due to Smooth Surface
· Smooth tissue passage
· Predictable loss and Higher strength compared to Catgut
specifications & Package
F a s t A b s o r b a b l e M o n o f i l a m e n t S u t u r e M a t e r i a l
MonoFast®Monosorb® Plus
IsO 13485Certified Quality System
IsO 13485Certified Quality System
Size Color & Packaging LengthCoating Materials
USP Metric 500m 1,000m
2 6
CHA
1 5
1-0 4
2-0 3.5
3-0 3
4-0 2
5-0 1.5
Size Color & Packaging LengthCoating Materials
USP Metric 250m
2 6
N/A
1 5
1-0 4
2-0 3.5
3-0 3
4-0 2
5-0 1.5
6-0 1
18 19P R O D U C T L I S T P R O D U C T L I S T
Antibacterial Synthetic Absorbable Monofilament Suture Material
DescriptionSynthetic Fast Absorbable PGA-PCL(75/25) Monofilament Suture material
Antibacterial agent contained suture
Non-sterile bulk strand
IndicationStrand for further processing to finished sterilized sutures for human and veterinary use
Characteristics· Compliance with the requirements of EP
· Excellent handling properties : Flexible, easy to tie
· Lower Incidence of Infection and Trauma due to Smooth Surface
· Smooth tissue passage
· Predictable loss and Higher strength compared to Catgut
specifications & Package
MonoFast® Plus
IsO 13485Certified Quality System
Description Synthetic Non-absorbable Polypropylene (PP) Monofilament Suture material, Non-sterile bulk strand
IndicationStrand for further processing to finished sterilized sutures for human and veterinary use
Characteristics· Compliance with the requirements of EP
· Excellent handling properties : flexible, easy to tie
· Lower Incidence of Infection and Trauma due to Smooth Surface
· Smooth tissue passage
· High strength
specifications & Package
IsO 13485Certified Quality System
Non-absorbable Polypropylene Monofilament Suture Material
Monolene®
Size Color & Packaging LengthCoating Materials
USP Metric 250m
2 6
CHA
1 5
1-0 4
2-0 3.5
3-0 3
4-0 2
5-0 1.5
Size Color & Packaging LengthCoating Materials
USP Metric 500m 1,000m
1 5
N/A
1-0 4
2-0 3.5
3-0 3
4-0 2
5-0 1.5
6-0 1
7-0 0.7
8-0 0.5
20 21P R O D U C T L I S T P R O D U C T L I S T
Us FDA Approved510(K) No. K984374
IsO 13485Certified Quality System
CE Mark Approved
1023
Surgisorb®
S y n t h e t i c A b s o r b a b l e S t e r i l e S u t u r e s
Description Sterile, ready to use coated synthetic bioabsorbable PGA sutures (with and without needle)
IndicationClosure of wounds or vessels
Characteristics· Comply with USP and EP requirements
· Reliable retention strength
- Average 75% at 14 days (in vitro, USP 2-0)
- Predictable absorption (loss of mass) in 60 to 90 days
· Available in violet or undyed (beige) color
· Supplied with one or three dozen in a carton
specifications
PolypropyleneNon-absorbable part
PGA-PCL(75/25) CompositeAbsorbable part
PolypropyleneNon-absorbable part
PGA-PCL(75/25) CompositeAbsorbable part
S y n t h e t i c P a r t i a l l y A b s o r b a b l e S u r g i c a l M e s h
Description Synthetic Partially Absorbable Polypropylene/PGA-PCL(75/25) Composite Surgical Mesh
Non-sterile/Sterile
IndicationSurgical mesh for repair of hernias or other soft tissue defects
Characteristics· Lightweight Mesh (PP amount <30g/m2) with excellent handling characteristics
- Proper initial stiffness like heavyweight mesh
- Proper burst strength with minimized amount of PP
· Segmented-pie monofilament structure
- Excellent flexibility after absorption (Soft mesh) comparing to other products
- Reduced risk of infection comparing with multifilament products
- Minimized pain and discomfort
· Better tissue attachement due to large pores
· Violet strips help accurate mesh positioning
· Reliable materials used for surgical sutures (PP, PGA-PCL(75/25))
specifications & Package
Proflex® Mesh
IsO 13485Certified Quality System
Size (cm) Packaging Unit
Non-Sterile Bulk Material Sterile Finished, Packaged Product
6 X 11 15pcs/Pouch 3pcs/Carton
10 X 15 15pcs/Pouch 3pcs/Carton
30 X 30 6pcs/Pouch 3pcs/Carton
SizeColor
Suture Length & Needle
Coating MaterialsUSP Metric
2 6
Various typesCa-Stearate
&PGA-PLA
1 5
1-0 4
2-0 3.5
3-0 3
4-0 2
5-0 1.5
6-0 1
7-0 0.7
8-0 0.5
22 23P R O D U C T L I S T P R O D U C T L I S T
Type Size (cm) Packaging Unit
Original
5 X 7.5 12pcs/Carton
5 X 35 12pcs/Carton
10 X 20 12pcs/Carton
1.25 X 5 12pcs/Carton
Fabric
5 X 7.5 12pcs/Carton
7.5 X 10 12pcs/Carton
15.2 X 22.9 10pcs/Carton
2.5 X 2.5 12pcs/Carton
2.5 X 7.5 12pcs/Carton
Fibrillar
2.5 X 5.1 10pcs/Carton
5.1 X 10.2 10pcs/Carton
10.2 X 10.2 10pcs/Carton
Non-Woven
2.5 X 5.1 10pcs/Carton
5.1 X 10.2 10pcs/Carton
10.2 X 10.2 10pcs/Carton
DescriptionAbsorbable knitted fabric composed by ORC (Oxidized Regenerated Cellulose)
Non-Sterile Bulk Material
IndicationSurgical procedures to assist in the control of capillary, venous, and small arterial hemorrhage
Characteristics· Compliance with the requirements of USP
· Plant-based product with minimal tissue reaction
· Antimicrobial effect with low pH
· Typical absorption in 2 weeks
specifications & Package
DescriptionAbsorbable knitted fabric composed by ORC (Oxidized Regenerated Cellulose)
Sterile Finished, Packaged Product
IndicationSurgical procedures to assist in the control of capillary, venous, and small arterial hemorrhage
Characteristics· Compliance with the requirements of USP
· Plant-based product with minimal tissue reaction
· Antimicrobial effect with low pH
· Typical absorption in 2 weeks
specifications & Package
O x i d i z e d r e g e n e r a t e d c e l l u l o s e h e m o s t a t O x i d i z e d r e g e n e r a t e d c e l l u l o s e h e m o s t a t
SurgiGuard® M SurgiGuard®
Type Size (cm) Packaging Unit
Original 25 X 70 3pcs/Pouch
Fabric 15.2 X 22.9 15pcs/Pouch
Fibrillar 23 X 25.5 1pcs/Pouch
Non-Woven 10.5 X 25.5 4pcs/Pouch
IsO 13485Certified Quality System
IsO 13485Certified Quality System
CE Mark Approved
2265
24 25P R O D U C T L I S T P R O D U C T L I S T
Us FDA Approved510(K) No. K990363
IsO 13485Certified Quality System
CE Mark Approved
1023
Description Yellowish, white, microporous and embossed membrane
Made of biodegradable polyglycolide, polylactide and d, ℓ- lactide / glycolide copolymer
IndicationIn severe cases of periodontal disease where patients are the risk of losing teeth
To restore the periodontal attachment apparatus that anchors teeth to the bone
Characteristics· Good biocompatibility · Good space making
· Rapid tissue incorporation · Easy clinical manageability
· Good cell-occlusiveness
specifications
Code Configuration Usage
DMB 1000 Single tooth narrow
DMB 2000 Single tooth wide
DMB 3000 Wraparound
DMB 4000 Interproximal
DMB 7000For use on dental implant
DMB 8000
Tooth
EpithelialTissue
Periodontalligament
Connectivetissue
Alveolarbone
BioMesh
GTR therapy using BioMesh
B i o d e g r a d a b l e G T R B a r r i e r
BioMesh®
O R C A d h e s i o n B a r r i e r
DescriptionAbsorbable knitted fabric composed by ORC (Oxidized Regenerated Cellulose)
Non-sterile/ Sterile
IndicationReducing the incidence of postoperative adhesions
Characterisctics· Oxidized Regenerated Cellulose is proved by FDA as anti-adhesion material
· Plant–based product with minimal tissue reaction
· Serves a solid synthetic membrane to physically separate tissues and organs during healing. Suitable to wrap organs
· Process of gelation starts within several days after implantation with the following complete degradation and absorption at 4 weeks
specifications & Package
InterGuard®
IsO 13485Certified Quality System
Size (cm) Packaging Unit
Non-Sterile Bulk Material Sterile Finished, Packaged Product
7.5 X 10 20pcs/Pouch 10pcs/Carton
12.5 X 15 20pcs/Pouch 10pcs/Carton
www.samyangbiopharm.com/eng
samyang Biopharmaceuticals Corporation6F, 295, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, KoreaT. 82-2-2157-9833 F. 82-2-2157-9062
MD Plant, Medical Devices55, Munpyeongseo-ro 18beon-gil, Daedeok-gu, Daejeon, Korea
samyang Biopharmaceuticals R&D Center5F, 295, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea